INPP5K Knockout HT29 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma epithelial cell line, in which the INPP5K gene has been disrupted to abolish functional protein expression. This loss-of-function model is generated through CRISPR/Cas9-mediated gene disruption, producing a heterogeneous pool of cells with targeted INPP5K knockout. The polyclonal format provides a robust cellular system for studying the global biological consequences of INPP5K deficiency without clonal selection bias, and is suited for applications where population-level analyses of signaling and phenotypic responses are required. Researchers can utilize these cells to dissect the tumor-suppressive roles of INPP5K and its impact on cancer-relevant pathways.
The HT29 host cell line originates from a human colon adenocarcinoma and is widely recognized for its capacity to differentiate into enterocyte-like cells under appropriate culture conditions. This characteristic, combined with its epithelial origin and well-documented molecular background, has established HT29 as a versatile model for colorectal cancer biology, intestinal epithelial differentiation, and drug response studies. The cells harbor mutations in key oncogenic pathways, including PIK3CA and TP53, which create a permissive genetic context for interrogating the contribution of additional regulators such as INPP5K. The use of HT29 as the parental line enables direct investigation of phosphoinositide signaling and cytoskeletal dynamics in a clinically relevant colon cancer setting.
INPP5K encodes an inositol polyphosphate 5-phosphatase that specifically dephosphorylates phosphatidylinositol (3,4,5)-trisphosphate (PIP3) to phosphatidylinositol (3,4)-bisphosphate (PI(3,4)P2), thereby terminating PIP3-mediated signaling. It functions downstream of the insulin receptor, IRS1, and PI3K (PIK3CA), and its activity suppresses membrane recruitment and phosphorylation of AKT1. INPP5K physically interacts with 14-3-3 proteins (YWHAB, YWHAZ), actin, and IRS1, linking PIP3 metabolism to cytoskeletal remodeling and cell migration. Loss of INPP5K results in sustained PIP3 accumulation, leading to hyperactivation of AKT1 and its downstream effectors such as mTORC1, while also releasing FOXO transcription factors from inhibitory phosphorylation, altering GLUT4 translocation and glucose uptake. This molecular network positions INPP5K as a critical rheostat balancing growth factor signaling and metabolic control.
In the HT29 colorectal adenocarcinoma context, INPP5K disruption magnifies the PI3K/AKT/mTORC1 signaling axis, potentially overriding tumor-suppressive constraints and promoting cellular proliferation, survival, and migration. Given that HT29 cells already exhibit upregulated PI3K activity due to endogenous PIK3CA mutation, INPP5K knockout may synergistically enhance oncogenic signaling, making this model highly relevant for studying pathway addictions and resistance mechanisms. Furthermore, the interplay between INPP5K and the actin cytoskeleton via its interaction with actin and 14-3-3 proteins provides a unique tool to examine how phosphoinositide metabolism drives epithelial-to-mesenchymal transition-like phenotypes and invasive behavior in colorectal cancer. This model also offers a platform to explore the metabolic consequences of deregulated insulin signaling in a cancerous context.
These polyclonal knockout cells are intended for a wide range of research applications, including mechanistic studies of PI3K/AKT signaling in colorectal cancer, phosphoinositide metabolism, and insulin pathway dysregulation. They are particularly suited for PI3K inhibitor response profiling, where INPP5K status may influence drug sensitivity, and for epithelial migration/invasion assays using transwell systems. Representative assays include western blotting for INPP5K, phosphorylated AKT1 (Ser473), and phosphorylated S6K; real-time quantitative PCR for downstream target genes; MTT or WST-1 proliferation assays; and immunofluorescence to visualize actin cytoskeleton reorganization. For further information or technical support, please contact Ascent Research.
